Author: Shi, Shihua; Wang, Fei; Li, Jiang; Li, Yulong; Li, Weihao; Wu, Xiaoping; Kou, Shuo; Wu, Yongcan; Wang, Xiaomin; Pei, Caixia; Huang, Demei; Qiu, Heng; Wang, Peili; Wang, Zhenxing
Title: The effect of Chinese herbal medicine on digestive system and liver functions should not be neglected in COVIDâ€19: An updated systematic review and metaâ€analysis Cord-id: qspu9v34 Document date: 2021_4_2
ID: qspu9v34
Snippet: Gastrointestinal symptoms and liver injury are common in patients with coronavirus disease 2019 (COVIDâ€19). However, profiles of different pharmaceutical interventions used are relatively underexplored. Chinese herbal medicine (CHM) has been increasingly used for patients with COVIDâ€19, but the efficacy of CHM used in COVIDâ€19 on gastrointestinal symptoms and liver functions has not been well studied with definitive results based on the updated studies. The present study aimed at testing t
Document: Gastrointestinal symptoms and liver injury are common in patients with coronavirus disease 2019 (COVIDâ€19). However, profiles of different pharmaceutical interventions used are relatively underexplored. Chinese herbal medicine (CHM) has been increasingly used for patients with COVIDâ€19, but the efficacy of CHM used in COVIDâ€19 on gastrointestinal symptoms and liver functions has not been well studied with definitive results based on the updated studies. The present study aimed at testing the efficacy of CHM on digestive symptoms and liver function (primary outcomes), the aggravation of COVIDâ€19, and the time to viral assay conversion (secondary outcomes), among patients with COVIDâ€19, compared with standard pharmacotherapy. The literature search was undertaken in 11 electronic databases from December 1, 2019 up to November 8, 2020. Appraisal of the evidence was conducted with Cochrane risk of bias tool or Newcastle Ottawa Scale. A randomâ€effects model or subgroup analysis was conducted when significant heterogeneity was identified in the metaâ€analysis. The certainty of the evidence was assessed with the grading of recommendations assessment, development, and evaluation approach. Fortyâ€eight included trials involving 4,704 participants were included. Metaâ€analyses favored CHM plus standard pharmacotherapy for COVIDâ€19 on reducing the aggravation of COVIDâ€19 and the time to viral assay conversion compared with standard pharmacotherapy. However, the present CHM as a complementary therapy for treating COVIDâ€19 may not be beneficial for improving most gastrointestinal symptoms and liver function based on the current evidence. More wellâ€conducted trials are warranted to confirm the potential efficacy of CHM furtherly.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date